Jacques Neefjes
Has grant
Professor, head department
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Jacques Neefjes is a Professor and Head of Department at Leiden University Medical Center in the Netherlands. His research focuses on innovative drug delivery strategies in glioblastoma, the development of antitumor agents, and the role of chromatin in cancer therapies. He has contributed significantly to the understanding of MHC-I binding and has explored metabolic engineering for anticancer drug biosynthesis. His recent work also includes the assessment of cardiotoxicity and epigenetic regulation in tumor cells.
Recent Grants
Grant: Close
Reintroducing aclarubicin in the treatment of relapsed and refractory AML patients
Open Date: 2018-07-01
Close Date: 2021-07-01
Grant: Close
Bacterial food poisoning and colon cancer; a cell biological and epidemiological study
Open Date: 2017-11-01
Close Date: 2021-11-01
Grant: Open
Oncology research
Open Date: 2017-01-01
Close Date: 2027-01-01
Grant: Close
ERC Adv Grant ER control of endosomal positioning
Open Date: 2016-09-01
Close Date: 2021-09-01
Grant: Close
The Institute for Chemical Immunology
Open Date: 2014-02-01
Close Date:
Articles (20)
Chromatinized DNA is targeted by proteins and small molecules to regulate chromatin function. For example, anthracycline cancer drugs evict nucleosomes in a mechanism that is still poorly understood. We here developed a flexible method for specific isotope labeling of nucleosomal DNA enabling NMR studies of such nucleosome interactions. We describe the synthesis of segmental one‐strand 13 C‐thymidine labeled 601‐DNA, the assignment of the methyl signals, and demonstrate its use to observe site‐specific binding to the nucleosome by aclarubicin, an anthracycline cancer drug that intercalates into the DNA minor grooves. Our results highlight intrinsic conformational heterogeneity in the 601 DNA sequence and show that aclarubicin binds an exposed AT‐rich region near the DNA end. Overall, our data point to a model where the drug invades the nucleosome from the terminal ends inward, eventually resulting in histone eviction and nucleosome disruption.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (19)
Sérgio F de Almeida
Universidade do Porto Faculdade de Medicina
Birol Cabukusta
Group leader / Assistant professor
University of Maastricht
Katerina Gurova
Associate Professor
Roswell Park Comprehensive Cancer Center
Ramon Arens
Associate Professor
Leiden University Medical Center
Johanna H Meijer
Professor
Leiden University Medical Center
Yassene Mohammed
University of Victoria
Benedikt Kessler
Professor of Biochemistry and Life Science Mass Spectrometry
University of Oxford
Steven Henikoff
Fred Hutchinson Cancer Research Center
Tom DeBoer
Associate professor
Leiden University Medical Center
Luis Moita
Associate Professor
Universidade Autónoma de Lisboa
Raffaella Gozzelino
NOVA University of Lisbon
Hugo van Ingen
-
Mirjam H.M. Heemskerk
Associate professor, Head of Laboratory of experimental hematology
Leiden University Medical Center
Jeroen T. Buijs
Leiden University Medical Center
Somayah Elsayed
Assistant Professor
Universiteit Leiden Instituut Biologie Leiden
Ana Marcu
University of Tübingen
Ilana Berlin
-
Ferenc Scheeren
Leiden University Medical Center
Ana Messias
Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit
Make your next move.
Prepare your application
Review drafts before you send them.